FAS -1,377 G/A polymorphism is associated with cancer susceptibility: Evidence from 10,564 cases and 12,075 controls

Human Genetics

Volumn 125, Issue 4, 2009, Pages 431-435

  Qiu, Li Xin ^a   Shi, Jian ^b   Yuan, Hui ^c   Jiang, Xin ^b   Xue, Kai ^a   Pan, Hai Feng ^c   Li, Jin ^a   Zheng, Ming Hua ^d  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; FAS ANTIGEN; GUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; ESOPHAGUS CANCER; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; OSTEOSARCOMA; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ANTIGENS, CD95; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 67349267967     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-009-0639-4     Document Type: Article

References (23)

1. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129
2. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28:2548-2551
3. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
4. Egger M, Smith DG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634
5. Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577-582
6. Kang S, Dong S, Seo SS (2008) FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180:1-5
7. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM (2007) Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol 29:815-821
8. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1478-1479
9. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC (2005) Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 99:113-118
10. Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE (2006a) Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16:253-263
11. Li C, Wu W, Liu J, Qian L, Li A, Yang K (2006b) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharmacogenet Genomics 16:245-251
12. Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78-85
13. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
14. Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI (2006) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54:303-308
15. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327-4330
16. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030-1036
17. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L (2005) FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202:967-974
18. Ter-Minassian M, Zhai R, Asomaning K (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29:2147-2152
19. Yang M, Sun T, Wang L (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14:3230-3236
20. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42:479-484
21. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12:5596-5602
22. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N (2007a) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28:1067-1073
23. Zhang H, Sun XF, Synnerstad I, Rosdahl I (2007b) Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: A case-control analysis. Cancer J 13:233-237